Search results
Results from the WOW.Com Content Network
Meloxicam has been shown, especially at low therapeutic doses, to selectively inhibit COX-2 over COX-1. [9] Meloxicam concentrations in synovial fluid range from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 times higher than in plasma, due to the lower albumin content in synovial fluid compared to plasma.
Studies of meloxicam 7.5 mg per day for 23 days find a level of gastric injury similar to that of a placebo, and for meloxicam 15 mg per day a level of injury lower than that of other NSAIDs; however, in clinical practice meloxicam can still cause some ulcer complications.
Tolmetin sodium is an approved NSAID, marketed for the treatment of rheumatoid arthritis, osteoarthritis and juvenile rheumatoid arthritis. [2] In humans, tolmetin sodium is absorbed rapidly with peak plasma levels observed 30 minutes after administration.
Pimobendan is indicated for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); [1] [7] and for use with concurrent therapy for congestive heart failure (e.g.,furosemide, etc.) as appropriate on a case-by-case basis. [1]
An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics (drugs used to relieve pain). Equianalgesic charts are used for calculation of an equivalent dose (a dose which would offer an equal amount of analgesia) between different analgesics. [1]
Dogs with confirmed cancer are treated with COX-2 inhibitor drugs, such as piroxicam, deracoxib, and meloxicam. These drugs halt disease progression in around 50% of dogs, shrink tumors in around 12%, and eliminate tumors in around 6%. [ 74 ]
Beta human chorionic gonadotrophin (β-hCG) In males and non-pregnant females: 5 [15] ... 0.7, [5] 1.0 [143] [144] 3.5, [143] 3.9, [5] 4.8 [144] x10 9 /L 16–25 [14 ...
Diflunisal is a salicylic acid derivative with analgesic and anti-inflammatory activity. [2] It was developed by Merck Sharp & Dohme in 1971, as MK647, after showing promise in a research project studying more potent chemical analogs of aspirin. [3]